TACR1 and osteosarcoma: There are three NK-1R antagonists that have shown activity in the treatment of osteosarcoma in vitro and in vivo: L-733,060, L-732,138, and FDA-approved aprepitant for the treatment of chemotherapy-induced nausea and vomiting (CINV) [5].